212 related articles for article (PubMed ID: 24375207)
1. Noninferiority of perphenazine vs. three second-generation antipsychotics in chronic schizophrenia.
Rosenheck R; Lin H
J Nerv Ment Dis; 2014 Jan; 202(1):18-24. PubMed ID: 24375207
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Capuano GA; Rosenheck RA; Keefe RS; Miller AL; Belz I; Hsiao JK;
Am J Psychiatry; 2007 Mar; 164(3):415-27. PubMed ID: 17329466
[TBL] [Abstract][Full Text] [Related]
3. What CATIE found: results from the schizophrenia trial.
Swartz MS; Stroup TS; McEvoy JP; Davis SM; Rosenheck RA; Keefe RS; Hsiao JK; Lieberman JA
Psychiatr Serv; 2008 May; 59(5):500-6. PubMed ID: 18451005
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Ramsey TL; Brennan MD
Schizophr Res; 2014 Dec; 160(1-3):73-9. PubMed ID: 25449714
[TBL] [Abstract][Full Text] [Related]
5. The CATIE schizophrenia effectiveness trial.
Delisi LE; Nasrallah HA
Schizophr Res; 2005 Dec; 80(1):v-vi. PubMed ID: 16291292
[No Abstract] [Full Text] [Related]
6. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial.
Keefe RS; Bilder RM; Davis SM; Harvey PD; Palmer BW; Gold JM; Meltzer HY; Green MF; Capuano G; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Davis CE; Hsiao JK; Lieberman JA; ;
Arch Gen Psychiatry; 2007 Jun; 64(6):633-47. PubMed ID: 17548746
[TBL] [Abstract][Full Text] [Related]
7. Olanzapine versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Duggan L; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Mar; (3):CD006654. PubMed ID: 20238348
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Lieberman JA; Stroup TS; McEvoy JP; Swartz MS; Rosenheck RA; Perkins DO; Keefe RS; Davis SM; Davis CE; Lebowitz BD; Severe J; Hsiao JK;
N Engl J Med; 2005 Sep; 353(12):1209-23. PubMed ID: 16172203
[TBL] [Abstract][Full Text] [Related]
9. Risperidone versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schwarz S; Schmid F; Hunger H; Kissling W; Leucht S
Cochrane Database Syst Rev; 2011 Jan; (1):CD006626. PubMed ID: 21249678
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study.
Volavka J; Czobor P; Citrome L; Van Dorn RA
CNS Spectr; 2014 Oct; 19(5):374-81. PubMed ID: 24284234
[TBL] [Abstract][Full Text] [Related]
11. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.
Stroup TS; Lieberman JA; McEvoy JP; Swartz MS; Davis SM; Rosenheck RA; Perkins DO; Keefe RS; Davis CE; Severe J; Hsiao JK;
Am J Psychiatry; 2006 Apr; 163(4):611-22. PubMed ID: 16585435
[TBL] [Abstract][Full Text] [Related]
13. Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Meyer JM; Davis VG; McEvoy JP; Goff DC; Nasrallah HA; Davis SM; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
Schizophr Res; 2008 Aug; 103(1-3):104-9. PubMed ID: 18534821
[TBL] [Abstract][Full Text] [Related]
14. Quetiapine versus other atypical antipsychotics for schizophrenia.
Komossa K; Rummel-Kluge C; Schmid F; Hunger H; Schwarz S; Srisurapanont M; Kissling W; Leucht S
Cochrane Database Syst Rev; 2010 Jan; (1):CD006625. PubMed ID: 20091600
[TBL] [Abstract][Full Text] [Related]
15. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.
Temmingh HS; Williams T; Siegfried N; Stein DJ
Cochrane Database Syst Rev; 2018 Jan; 1(1):CD011057. PubMed ID: 29355909
[TBL] [Abstract][Full Text] [Related]
16. Clozapine versus other atypical antipsychotics for schizophrenia.
Asenjo Lobos C; Komossa K; Rummel-Kluge C; Hunger H; Schmid F; Schwarz S; Leucht S
Cochrane Database Syst Rev; 2010 Nov; (11):CD006633. PubMed ID: 21069690
[TBL] [Abstract][Full Text] [Related]
17. The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.
Bellavia A; Centorrino F; Jackson JW; Fitzmaurice G; Valeri L
Schizophr Res; 2019 Apr; 206():96-102. PubMed ID: 30584025
[TBL] [Abstract][Full Text] [Related]
18. Interpreting the results of the CATIE study.
Pandiani JA; Banks SM
Psychiatr Serv; 2006 Jan; 57(1):140-1. PubMed ID: 16399981
[No Abstract] [Full Text] [Related]
19. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study.
Swartz MS; Wagner HR; Swanson JW; Stroup TS; McEvoy JP; Reimherr F; Miller DD; McGee M; Khan A; Canive JM; Davis SM; Hsiao JK; Lieberman JA;
Schizophr Res; 2008 Mar; 100(1-3):39-52. PubMed ID: 18191383
[TBL] [Abstract][Full Text] [Related]
20. Did CATIE influence antipsychotic use?
Citrome L; Jaffe A; Martello D; Allingham B; Levine J
Psychiatr Serv; 2008 May; 59(5):476. PubMed ID: 18451000
[No Abstract] [Full Text] [Related]
[Next] [New Search]
